Prognostic characteristics of surgical stage I endometrial adenocarcinoma

Konski, André; Domenico, Don R.; Tyrkus, Michael; Irving, Douglas; Neisler, James; Phibbs, G.; Zeidner, Steven; Eggleston, William

doi:10.1016/0360-3016(96)00189-7

Cited by 26 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specific binding sites for GnRH were demonstrated in human breast carcinomas but not in non-neoplastic breast tissue by ligand immunoblotting back in 1985 [18]. The percentage of GnRH R positive tissues here (54.2%) is in line with previous reports detecting binding sites by a multipoint assay [11].…”

Section: Discussionsupporting

confidence: 91%

“…Our study confirms that they represent the protein product of this gene. Similarly, the low affinity GnRH-binding sites described in human breast cancer cell lines (ZR-75-1, MDA-MB-231, Sk Br 3, MDA-MB-157 and MCF-7) [18] obviously represent the GnRH R gene product detected here in MDA-MB231 and MCF7 but not in T47 human breast cancer cell lines. The high GnRH neuropeptide levels detected in T47 might down-regulate receptor expression.…”

Section: Discussionsupporting

confidence: 62%

See 1 more Smart Citation

Gonadotropin-releasing hormone neuropeptides and receptor in human breast cancer: Correlation to poor prognosis parameters

et al. 2013

View full text Add to dashboard Cite

a b s t r a c tExpression of the two gonadotropin-releasing hormone homologue peptides GnRHI and GnRHII and their receptor GnRHR has been demonstrated in a number of malignancies. In hormone-dependent breast cancer, GnRH analogs are used for therapy in premenopausal women. Gene expression of GnRHI, II and R was studied in breast biopsies from primary breast adenocarcinoma obtained from the tumor and the adjacent benign tissue. Levels were evaluated by a multiplex real-time RT-PCR. GnRHI transcripts were detected in 14.7% of the benign and 29.4% malignant biopsies and GnRHII in 21.2% benign and 44.1% malignant biopsies. GnRHR was also more frequent in the malignant (54.2%) than in the benign (24.0%) biopsies, at similar expression levels. No transcripts were detected in biopsies from healthy individuals. There was a strong correlation between the presence of GnRHI and GnRHII transcripts and their receptor in the benign and the malignant biopsies. GnRHI, II and R expression correlated significantly with poor prognosis pathological parameters. Immunohistochemistry for GnRHR revealed expression in malignant cells and in epithelial cells of mammary ducts of the adjacent area with pre-cancerous features. In contrast, GnRH I and II peptides were rarely expressed at low levels in breast cancer cells. In conclusion GnRH peptides and receptor are expressed more frequently in breast tumors than in the adjacent mammary tissue, representing a malignant feature. Their expression correlated to tumor characteristics of poor prognosis and was therefore related to more aggressive malignancies. Concomitant expression of peptides and receptor supports an autocrine/paracrine regulating role.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 62%

Gonadotropin-releasing hormone neuropeptides and receptor in human breast cancer: Correlation to poor prognosis parameters

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In einem ersten Schritt werden sämtliche ordinalskalierten molekularen und (Emons et al, 2000;Martin et al, 1983 (Konski et al, 1996;Creasman et al, 1998 (Grulich et al, 1996;Lindahl et al, 1992Lindahl et al, , 1994 Prognosefaktoren um etwa 20% zu erhöhen vermag (Löning et al, 1999). (Grulich et al, 1996;Schenker et al, 1980).…”

Section: Expression Des Progesteronrezeptors Im Tumorgewebeunclassified

Prognosefaktoren des Endometriumkarzinoms - Ein Vergleich klinischer und immunhistochemisch bestimmter Parameter

Brohn¹,

Kullmer²,

Knoblauch³

et al. 2004

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

In den meisten Fällen erfolgt die Diagnose Endometriumkarzinom in einem frühen, doch auch in ca. 20 % in einem fortgeschrittenen Stadium. Welche tumorbiologischen Eigenschaften führen dazu, dass einige Endometriumkarzinome erst in fortgeschrittenen Stadien entdeckt werden? Material und Methodik: Ein Kollektiv von 183 Patientinnen mit Karzinomen des Endometriums wurde reevaluiert im Hinblick auf das klinische Follow-up sowie der Histopathologie (myometrane Tumorinvasionstiefe, Tumortyp, Grading, Lymphangiosis und Hämangiosis carcinomatosa, Tumornekrose). Zusätzlich erfolgten immunhistochemische Färbungen zur Detektion der Expression von Östrogen-und Progesteronrezeptor, Fibronektin und Faktor VII aktivierende Protease (FSAP) unter Verwendung der Streptavidin-Biotin-Methode. Mithilfe der Kaplan-Meier-Überlebenszeitanalyse wurden die prognostischen Parameter analysiert; bivariate Korrelationen sowie einfache und schrittweise Diskriminanzanalyse ermöglichten die Analyse der Relevanz der genannten Faktoren im Hinblick auf die Tumorprogression. Ergebnisse: Tumorstadium (FIGO) und Hämangiosis carcinomatosa konnten als wichtigste Prognosefaktoren des Endometriumkarzinoms identifiziert werden. Hinsichtlich der o. g. Fragestellung wurde die Lymphangiosis carcinomatosa als wichtigster

show abstract

“…More than 75% of endometrial cancers are still confined to the uterus at diagnosis (stage I) [3,4]. Among the most important predictors of local and distant recurrence for stage I tumours are the level of differentiation and the depth of the myometrial invasion [5].…”

Section: Introductionmentioning

confidence: 99%

Impact of External Radiotherapy on Survival after Stage I ndometrial Cancer: Results from a Population-Based Study

Tebeu¹,

Verkooijen²,

Popowski³

et al. 2011

JCST

View full text Add to dashboard Cite

Purpose: To assess the impact of external radiotherapy on the survival of patients with early stage endometrial cancer in a population-based setting. Patients and methods:Using information from the Geneva Cancer Registry, we identified all patients who underwent operations for endometrial cancer between 1980 and 1996. We excluded patients with tumours that had spread beyond the uterus, patients without myometrial invasion and patients with poorly differentiated, deeply invasive tumours. Adjusting for other prognostic variables, a Cox proportional hazards analysis was used to calculate the diseasespecific risks and the overall mortality risks in patients treated with brachytherapy or external radiotherapy compared with non-irradiated patients. Stratified analyses were performed for patients with 'low-risk' (superficial myometrial invasion, grades 1-2) and 'high-risk' (superficial invasion grade 3 or deep invasion grades 1-2) tumours. Results:For the 162 patients with low-risk tumours, external radiotherapy was significantly associated with an increased overall mortality (hazard ratio [HR]: 6.4, 95% CI: 1.3-30.2) and endometrial cancer mortality (HR: 9.4, 95% CI: 1.0-86.7). In the group of patients with high-risk tumours (n=108), neither brachytherapy nor external radiotherapy modified the endometrial cancer mortality risk. Conclusion:External radiotherapy does not reduce mortality from early stage endometrial cancer and is associated with a significantly increased overall and endometrial cancer mortality risk among patients with superficially invasive grade 1-2 tumours. .

show abstract

Prognostic characteristics of surgical stage I endometrial adenocarcinoma

Cited by 26 publications

References 23 publications

Gonadotropin-releasing hormone neuropeptides and receptor in human breast cancer: Correlation to poor prognosis parameters

Gonadotropin-releasing hormone neuropeptides and receptor in human breast cancer: Correlation to poor prognosis parameters

Prognosefaktoren des Endometriumkarzinoms - Ein Vergleich klinischer und immunhistochemisch bestimmter Parameter

Impact of External Radiotherapy on Survival after Stage I ndometrial Cancer: Results from a Population-Based Study

Contact Info

Product

Resources

About